BCTXL

Briacell Therapeutics Corp

• TipRanks·1d ago

  BriaCell announces data from Bria-IMT at ASCO 2026

• Benzinga·1d ago

  BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual Meeting

• PUBT·1d ago

  BriaCell reports 16.6-month median survival in Phase 2 Bria-IMT breast cancer study

• Benzinga·05/15 11:38

  BriaCell Therapeutics Announces Progress In Developing Bria-OVA+, Next Gen, Personalized, Off-The-Shelf, Cell-Based Immunotherapy For Ovarian Cancer

• PUBT·05/15 11:31

  BriaCell adds ovarian cancer immunotherapy candidate Bria-OVA+ to pipeline

• Reuters·05/15 11:30

  BRIACELL EXPANDS PIPELINE TO INCLUDE AN OVARIAN CANCER IMMUNOTHERAPY CANDIDATE, BRIA-OVA+™

• TipRanks·05/14 14:11

  BriaCell completes manufacturing for prostate cancer clinical supplies

• Benzinga·05/14 11:39

  BriaCell Therapeutics Completes Manufacturing Clinical Supplies Of Bria-PROS+ For Prostate Cancer

• TipRanks·05/13 14:41

  BriaCell adds Penn Medicine as Phase 3 breast cancer study site

• Benzinga·05/13 11:33

  BriaCell Therapeutics Adds Penn Medicine's Abramson Cancer Center As Clinical Trial Site In BriaCell's Ongoing Pivotal Phase 3 Clinical Study

• Benzinga·05/12 11:32

  BriaCell Therapeutics\ Pivotal Phase 3 Bria-ABC Trial Enrolls 230 Participants

• PUBT·05/12 11:30

  BriaCell Phase 3 Bria-IMT breast cancer trial enrollment tops 230 patients

• Reuters·05/12 11:30

  BRIACELL THERAPEUTICS CORP - INTERIM TOPLINE DATA FROM PHASE 3 BRIA-ABC STUDY EXPECTED IN 2026

• PUBT·05/07 11:31

  BriaCell adds NYU Langone Perlmutter as site for Phase 3 breast cancer trial